Autopsy report · NCT02992964

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

“Withdrawal of drug supply/funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 years 6 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

The Hospital for Sick Children

Sponsor type

University, hospital or other

Conditions

Refractory or Recurrent Hypermutated Malignancies; Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients

Interventions

Nivolumab

Participants

11

Sites

10

Countries

Australia, Canada, France, Israel, United States

Trials that died the same way

• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (81% match in meaning)
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
  “Withdrawal of funding” (77% match in meaning)
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (77% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (76% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.